Akari Therapeutics Plc financial data

Symbol
AKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
22 Boston Wharf Road, Fl 7, Boston, MA
State of incorporation
United Kingdom
Former names
Celsus Therapeutics Plc. (to 9/15/2015), Morria Biopharmaceuticals PLC (to 6/20/2013)
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 16.4 %
Return On Equity -956 % -123%
Return On Assets -138 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57.8B shares +264%
Common Stock, Shares, Outstanding 53.2B shares +302%
Entity Public Float 14M USD +2.94%
Common Stock, Value, Issued 5.32M USD +302%
Weighted Average Number of Shares Outstanding, Basic 23.9B shares +144%
Weighted Average Number of Shares Outstanding, Diluted 23.9B shares +144%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 6.98M USD +28.1%
General and Administrative Expense 1.28M USD -44.2%
Operating Income (Loss) -21.6M USD -28.8%
Nonoperating Income (Expense) 1.85M USD -72.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -19.8M USD -97.8%
Earnings Per Share, Basic 0 USD/shares -69%
Earnings Per Share, Diluted 0 USD/shares -69%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.6M USD -32.4%
Other Assets, Current 201K USD +2.03%
Assets, Current 2.95M USD -32%
Property, Plant and Equipment, Net 31.8K USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Intangible Assets, Net (Excluding Goodwill) 14K USD -17.6%
Goodwill 8.43M USD
Other Assets, Noncurrent 11.1K USD
Assets 50.6M USD +1061%
Accounts Payable, Current 12.4M USD +642%
Accrued Liabilities, Current 3.14M USD +100%
Liabilities, Current 19.9M USD +334%
Deferred Income Tax Liabilities, Net 8.04M USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 383K USD +66.1%
Liabilities 28.3M USD +518%
Accumulated Other Comprehensive Income (Loss), Net of Tax -738K USD +29%
Retained Earnings (Accumulated Deficit) -247M USD -8.7%
Stockholders' Equity Attributable to Parent 22.2M USD
Liabilities and Equity 50.6M USD +1061%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.04M USD +17.1%
Net Cash Provided by (Used in) Financing Activities 1.51M USD -52.9%
Common Stock, Shares Authorized 245B shares +443%
Common Stock, Shares, Issued 53.2B shares +302%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.54M USD -52%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.66M USD -30.8%
Deferred Tax Assets, Valuation Allowance 60.3M USD +42.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.19 pure
Deferred Tax Assets, Gross 60.4M USD +33.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.5M USD -89.6%
Property, Plant and Equipment, Gross 753K USD -11.2%
Operating Lease, Liability, Current 4.6M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 56.7M USD +31.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 19.9M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 13K USD +1200%
Deferred Tax Assets, Net of Valuation Allowance 96K USD -96.7%
Share-based Payment Arrangement, Expense 2.25M USD +95.2%
Interest Expense 51K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares